Germline mutations in the TP53 gene
- PMID: 8718514
Germline mutations in the TP53 gene
Abstract
Since the majority of germline mutations in the TP53 gene seem to occur in LFS or LFL families, and these are rare, research is best conducted in a collaborative setting (Li and Fraumeni, in press). In a report from a meeting at Bethesda in 1993, the following areas were outlined for collaborative study: the correlation (if any) of phenotypes with specific mutation; age specific penetrance; cumulative cancer incidence; gender differences in tumour development in carriers; the effects of DNA damaging agents on individuals with a TP53 mutation; the frequency of TP53 germline mutations in cohorts of patients with rare childhood tumours (eg adrenocortical carcinoma); and the psychosocial aspects of predictive TP53 testing. In addition, if, as seems likely from recent data, X irradiation in these individuals induces DNA damage that is tolerated, urgent collaborative studies are needed to investigate new methods of screening, such as magnetic resonance imaging. Treatment modalities should be carefully chosen, and for this reason alone, predictive testing may be desirable in all LFS and LFL families. Individuals carrying TP53 mutations could be offered chemoprevention within trials in an effort to reduce their mortality from cancer.
Similar articles
-
TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.J Med Genet. 2010 Jun;47(6):421-8. doi: 10.1136/jmg.2009.073429. J Med Genet. 2010. PMID: 20522432
-
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.Cancer Res. 2003 Oct 15;63(20):6643-50. Cancer Res. 2003. PMID: 14583457
-
Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.Cancer Res. 1997 Aug 1;57(15):3245-52. Cancer Res. 1997. PMID: 9242456
-
Germline TP53 mutations and Li-Fraumeni syndrome.Hum Mutat. 2003 Mar;21(3):313-20. doi: 10.1002/humu.10185. Hum Mutat. 2003. PMID: 12619118 Review.
-
Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome.Curr Opin Oncol. 2010 Jan;22(1):64-9. doi: 10.1097/CCO.0b013e328333bf00. Curr Opin Oncol. 2010. PMID: 19952748 Review.
Cited by
-
Li-Fraumeni Syndrome.J Pediatr Genet. 2016 Jun;5(2):84-8. doi: 10.1055/s-0036-1579759. Epub 2016 Apr 13. J Pediatr Genet. 2016. PMID: 27617148 Free PMC article. Review.
-
Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant.Nat Commun. 2019 Nov 7;10(1):5061. doi: 10.1038/s41467-019-13002-x. Nat Commun. 2019. PMID: 31699989 Free PMC article.
-
Rectal leiomyosarcoma as the initial phenotypic manifestation of Li-Fraumeni-like syndrome: a case report and review of the literature.J Med Case Rep. 2022 Dec 19;16(1):468. doi: 10.1186/s13256-022-03671-6. J Med Case Rep. 2022. PMID: 36529791 Free PMC article. Review.
-
A first report of a rare TP53 variant associated with Li-Fraumeni syndrome manifesting as invasive breast cancer and malignant solitary fibrous tumor.World J Surg Oncol. 2021 Aug 27;19(1):254. doi: 10.1186/s12957-021-02370-8. World J Surg Oncol. 2021. PMID: 34452612 Free PMC article.
-
Number of rare germline CNVs and TP53 mutation types.Orphanet J Rare Dis. 2012 Dec 21;7:101. doi: 10.1186/1750-1172-7-101. Orphanet J Rare Dis. 2012. PMID: 23259501 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Molecular Biology Databases
Research Materials
Miscellaneous